Genocea Biosciences Inc. Stock
-
Your prediction
Genocea Biosciences Inc. Stock
Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Pros and Cons of Genocea Biosciences Inc. in the next few years
Pros
Cons
Performance of Genocea Biosciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - | - | - | - |
| Evolus Inc | -2.140% | -7.576% | -26.210% | -71.181% | -32.844% | -57.442% | -36.237% |
| Madrigal Pharmaceuticals inc. | 1.980% | -2.180% | -15.435% | 27.021% | -18.997% | 56.512% | 304.934% |
| Heron Therapeutics Inc. | 2.350% | -5.009% | 1.336% | -38.542% | -4.668% | -64.997% | -93.440% |
Comments
